Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Sandhaus

Pulmonary Disease Denver, CO Medical Doctor

NPI 1093884652 CMS profile 186120

1400 Jackson St, Denver, CO 80206

Open in the dashboard

General payments

$101,678

83 records reported · program years 2019–2025

Research payments

$5,085

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$96,255 paid to institutions, not to them · program years 2020–2021

Through program year 2025, Robert Sandhaus of Denver, CO is reported in the CMS Open Payments database as having received $101,678 across 83 general payments and $5,085 in research payments paid to them. Separately, studies naming them as principal investigator received $96,255 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,964 11
2025 Research $5,085 3
2024 General $20,946 12
2023 General $7,966 6
2022 General $882 4
2021 General $9,249 5
2020 General $27,904 12
2019 General $26,767 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Sandhaus
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Robert Sandhaus were reported at $7,964. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Robert Sandhaus Pulmonary Disease median Middle half National median
2019 $26,767 $377 $109–$1,340 $163
2020 $27,904 $230 $56–$907 $114
2021 $9,249 $269 $68–$1,072 $132
2022 $882 $390 $100–$1,457 $149
2023 $7,966 $419 $114–$1,659 $160
2024 $20,946 $476 $123–$1,818 $164
2025 $7,964 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CSL Behring $45,272 21 payments
  2. Grifols USA, LLC $17,304 21 payments
  3. Genzyme Corporation $14,907 6 payments
  4. Grifols Shared Services North America, Inc. $6,816 8 payments
  5. GlaxoSmithKline, LLC. $4,550 1 payment
  6. Takeda Pharmaceuticals U.S.A., Inc. $4,460 5 payments
  7. Grifols Canada Ltd. $3,600 3 payments
  8. AstraZeneca AB $3,150 4 payments
  9. Vertex Pharmaceuticals Incorporated $1,334 7 payments
  10. Relypsa, Inc. $183 6 payments
  11. Other $102 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $48,189 16 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $26,541 10 payments
  3. Travel and Lodging $12,735 13 payments
  4. Honoraria $12,235 3 payments
  5. Food and Beverage $1,970 40 payments
  6. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. Zemaira Pulmonary/Respiratory Diseases $35,292 20 payments
  2. Prolastin-C Liquid $23,883 27 payments
  3. GLASSIA $4,420 4 payments
  4. Veltassa Nephrology $118 1 payment
  5. DUPIXENT $102 1 payment
  6. KALYDECO $99 1 payment
  7. Veltassa Hyperkalemia $22 1 payment
  8. Zemaira Pulmonary/Respiratory Diseases $19 1 payment
  9. Prolastin-C $12 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $5,085 3 payments

Records

86 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record